Search
Registration & accommodation
Registration is closed
Individual RegistrationHybrid registration fee includes:
Access to the scientific and educational sessions of the meeting
Networking opportunities to speak with the faculty during breaks and the welcome reception
Coffee/tea breaks on November 2-4 and lunches on November 3 and 4
Access to…
EHA Research Conference 2022
Dates: October 17-20, 2022
Location: Palermo (Sicily), Italy
Chairs: Emmanuelle Passegué, Cristina Lo Celso, Mick Milsom, Meri Alberich Jorda, Antonella Fidanza, Jürg Schwaller, Thomas Mercher and Brian Huntly
Registration is closed
EHA is proud to announce the inaugural edition of the EHA Research Conference,…
EHA-SWG Diagnosis Teaser Meeting
On February 17 the 'teaser' meeting "Join the conversation on integrated diagnosis" with Prof MC Béne and key opinion experts took place virtually. Missed the live teaser? No worries, you can still watch the recording until March 17, 2022.
Read moreCarrerasLeaders call two is now open
The second CarrerasLeaders call is open: apply now to the postdoctoral program to empower future leaders in the fight against blood cancers.
Read moreUkraine Bridge Funding - information for applicants
The EHA Ukraine Bridge Funding Program is a 1-year non-clinical funding opportunity for Ukrainian hematologists and researchers in hematology (see press release here), now in collaboration with the American Society of Hematology, which will participate in funding and the selection…
Read moreMeeting Program
For the program please click here.
If you would like a printable / PDF version of the program, you can download it via the 'Scientific Programme' tab in the above linked planner.
EHA-LSHBT Virtual Hematology Updates
EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.
Read moreFDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- »